Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
- Author:
Sang wook LEE
1
;
Eun Kyung CHOI
;
Suk Joong OH
;
Cheol Won SUH
;
Sang We KIM
;
Jung Shin LEE
;
Dong Soon KIM
;
Won Dong KIM
;
Woo Seong KIM
;
Sang Do LEE
;
Jong Hoon KIM
;
Seung Do AHN
;
Kyoung Ju KIM
;
Young Ju NOH
Author Information
1. Department of Radiation Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea. ekchoi@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Concurrent chemoradiation;
Conformal radiotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Cisplatin*;
Drug Therapy;
Esophagitis;
Follow-Up Studies;
Humans;
Karnofsky Performance Status;
Lung Neoplasms*;
Lung*;
Paclitaxel*;
Prospective Studies;
Radiotherapy;
Radiotherapy, Conformal;
Survival Rate;
Tumor Burden;
Weight Loss
- From:Cancer Research and Treatment
2002;34(5):345-351
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the feasibility, toxicity and response rate, of concurrent chemoradiation therapy with paclitaxel/cisplatin in stage III locally advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Between May 1999 and December 2000, 80 patients with stage III NSCLC were enrolled in a prospective protocol. Radiotherapy was given to a total dose of 70.2 Gy (daily fraction of 1.8 Gy for 5 days), over an 8 week period, on the gross tumor volume, combined with chemotherapy. The concurrent chemotherapy consisted of paclitaxel (40 mg/m2) and 20 mg/m2 cisplatin per week for 8 consecutive weeks. All patients received 3-D conformal radiotherapy using CT-simulated planning. Acute toxicities were evaluated by the RTOG scale. The median follow-up period was 16 months, ranging from 3 to 29 months. RESULTS: Of the 80 patients, 71 received treatment per protocol, with minor variation of protocol delivery. The median age of the patients was 60 years. Karnofsky Performance status were 100 and 90 in 62 patients, and 80 and 70 in 9, respectively. Weight loss of less than 5% for 6 months was observed in 22 patients. The response to treatment was evaluated from the radiological findings. Complete and partial responses were observed in 8 and 51 patients, respectively. Ultimately, 82% of patients (included complete responses: 8 cases) obtained more than a partial response. Although, radiation induced esophagitis was the most common treatment related toxicity, occurring in 44 patients (69%), severe radiation esophagitis like, grade 3, was observed in only 3 patients, and the most acute toxicities had completely recovered 1 month following treatment. The overall 2-year actuarial and progression free survivals were 56 and 45%, respectively. CONCLUSION: This combined modality has activity with manageable toxicity and 23 months in mean survival time in patients with stage III NSCLC. A longer follow up will be required to realise the expected higher survival of these results.
